DE69828635D1 - Feste lösungskügelchen - Google Patents

Feste lösungskügelchen

Info

Publication number
DE69828635D1
DE69828635D1 DE69828635T DE69828635T DE69828635D1 DE 69828635 D1 DE69828635 D1 DE 69828635D1 DE 69828635 T DE69828635 T DE 69828635T DE 69828635 T DE69828635 T DE 69828635T DE 69828635 D1 DE69828635 D1 DE 69828635D1
Authority
DE
Germany
Prior art keywords
solid solution
surfactant
polyoxyethylene
hydrophobic
solution beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828635T
Other languages
English (en)
Other versions
DE69828635T2 (de
Inventor
A Burnside
Guinness M Mc
M Rudnic
A Couch
Xiaodi Guo
K Tustian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Shire Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Laboratories Inc filed Critical Shire Laboratories Inc
Application granted granted Critical
Publication of DE69828635D1 publication Critical patent/DE69828635D1/de
Publication of DE69828635T2 publication Critical patent/DE69828635T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
DE69828635T 1997-09-19 1998-09-18 Feste lösungskügelchen Expired - Lifetime DE69828635T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5940897P 1997-09-19 1997-09-19
US59408P 1997-09-19
PCT/US1998/019658 WO1999013864A2 (en) 1997-09-19 1998-09-18 Solid solution beadlet

Publications (2)

Publication Number Publication Date
DE69828635D1 true DE69828635D1 (de) 2005-02-17
DE69828635T2 DE69828635T2 (de) 2005-06-16

Family

ID=22022768

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828635T Expired - Lifetime DE69828635T2 (de) 1997-09-19 1998-09-18 Feste lösungskügelchen

Country Status (9)

Country Link
US (1) US6692767B2 (de)
EP (1) EP1028712B1 (de)
JP (1) JP2002522354A (de)
AT (1) ATE286721T1 (de)
AU (1) AU9496798A (de)
CA (1) CA2302275C (de)
DE (1) DE69828635T2 (de)
ES (1) ES2236943T3 (de)
WO (1) WO1999013864A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819273A1 (de) 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
SK12822002A3 (sk) * 2000-03-30 2003-02-04 Bristol-Myers Squibb Company Perličky s trvalým uvoľňovaním obsahujúce stavudín
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
ES2231717T3 (es) * 2001-05-03 2005-05-16 F. Hoffmann-La Roche Ag Forma de dosificacion farmaceutica del mesilato de melfinavir amorfo.
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
ES2739852T3 (es) 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
KR101061351B1 (ko) 2002-04-09 2011-08-31 플라멜 테크놀로지스 활성 성분 마이크로캡슐의 경구 현탁액
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
US10004729B2 (en) * 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP1594467A4 (de) * 2002-07-05 2008-10-22 Collegium Pharmaceutical Inc Missbrauch verhindernde pharmazeutische zusammensetzungen von opioiden und anderen medikamenten
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0416534A (pt) 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
CA2583439C (en) * 2004-09-24 2016-05-10 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP5290198B2 (ja) * 2006-12-20 2013-09-18 ミラン ファーマシューティカルズ ユーエルシー ホットメルト顆粒化潤滑剤を含んでなる医薬組成物
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
EP2216015A4 (de) * 2007-11-02 2012-12-19 So Pharmaceutical Corp Komplex aus einem stoff mit geringer löslichkeit und einem tensid sowie verfahren zu seiner herstellung
JP2011505157A (ja) * 2007-12-05 2011-02-24 ディーエスエム アイピー アセッツ ビー．ブイ． 脂溶性活性成分の微粉砕状調合物
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
RU2015144851A (ru) 2009-06-18 2019-01-10 Серенити Фармасьютикалз, Элэлси Безопасное применение десмопрессина
EP2305742B1 (de) * 2009-10-01 2017-02-22 Symrise AG Sphärisches Kern-Schalen-Teilchen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
BRPI0906820A2 (pt) * 2009-12-21 2013-07-30 Inst Presbiteriano Mackenzie matriz cerÂmica para incorporar fÁrmacos de liberaÇço controlada, comprimido, mÉtodo para obtenÇço da matriz cerÂmica e mÉtodo para produzir um comprimido
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
EP2887935A1 (de) * 2012-08-22 2015-07-01 XenoPort, Inc. Orale dosierformen von methylwasserstofffumarat und prodrugs davon
CA2884270A1 (en) * 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Sustained release oral dosage forms comprising low melting propionic acid derivative particles
CN104640570B (zh) * 2012-09-18 2017-04-26 麦克内尔-Ppc股份有限公司 包含低熔点丙酸衍生物颗粒的混悬药物制剂
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10098874B2 (en) * 2016-04-28 2018-10-16 Amplipharm Pharmceuticals, Llc Temozolomide powder formulation
US10285987B2 (en) 2017-04-28 2019-05-14 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
US9949967B2 (en) * 2016-04-28 2018-04-24 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
IT202000022126A1 (it) * 2020-09-18 2022-03-18 Nutrilinea S R L Procedimento per preparare formulazioni solide comprendenti un composto idrofobico disperdibili in un liquido a freddo e relative formulazioni solide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857933A (en) * 1969-10-17 1974-12-31 Hoechst Ag Process for the manufacture of a drug dosage form permitting controlled release of active ingredient
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
KR960005137B1 (ko) 1989-11-13 1996-04-22 노바 파머수티컬 코포레이션 물질 전달용 리포스피어
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
BE1009257A3 (nl) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Farmaceutische matrix.

Also Published As

Publication number Publication date
JP2002522354A (ja) 2002-07-23
US6692767B2 (en) 2004-02-17
WO1999013864A2 (en) 1999-03-25
EP1028712B1 (de) 2005-01-12
CA2302275A1 (en) 1999-03-25
ES2236943T3 (es) 2005-07-16
AU9496798A (en) 1999-04-05
DE69828635T2 (de) 2005-06-16
CA2302275C (en) 2009-12-08
ATE286721T1 (de) 2005-01-15
US20010006650A1 (en) 2001-07-05
WO1999013864A3 (en) 1999-08-12
EP1028712A2 (de) 2000-08-23

Similar Documents

Publication Publication Date Title
DE69828635D1 (de) Feste lösungskügelchen
KR970704695A (ko) 인돌리진 sPLA₂억제제(INDOLIZINE sPLA₂INHIBITORS)
DK0839525T3 (da) Præparat med forlænget frigivelse
ATE286655T1 (de) Raumtemperatur-sterilisierungsmittel
ATE172359T1 (de) Kalt-sterilisermittel mit verlängerter aktivät
ATE41739T1 (de) Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.
NO20000467L (no) Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
DK415689A (da) Farmaceutiske midler
AR015715A1 (es) Una composicion acondicionadora del cabello
SE9700061D0 (sv) Controlled release composition
EE04179B1 (et) Liitlipiidide kasutamine stabiliseerivate lisanditena seedeensüümide segude ravimpreparaatides
DE69417496T2 (de) Sulfonierung von Fettsäureestern
DK0703897T3 (da) Lipoxinforbindelser med forlænget halveringstid
DE60014369D1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
NO954506D0 (no) Hellbare, topiske formuleringer inneholdende polymert materiale, glycoler og glycerider
DK1313511T3 (da) Testosteronesterformulering til human brug
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
EP0180568A3 (de) Auftaumaterial
BR9808140A (pt) Formulação unitária
DE3883098T2 (de) Sprühgetrocknete Ibuprofen-Zusammensetzungen.
NO992818L (no) Anvendelse av pereddiksyre i fiskeoppdrett
BR9705425A (pt) Preparações pulverulentas dispersíveis em água.
IT1232917B (it) Procedimento per la fabbricazione di microsfere tramite reticolazionedi proteine, microsfere cosi' ottenute e loro impieghi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SUPERNUS PHARMACEUTICALS, INC., ROCKVILLE, MD., US